REGN
Regeneron Pharmaceuticals, Inc.
$955.47+4.28 (+0.45%)Close Nov 13, 2026
Insider trading
12 months to Nov 6, 2026- Sold
- $58.2M
- 11 insiders
- Largest seller
- $20.4M
- George L. Sing · 35% of sales
- Plan sales
- $14.6M
- 25% of sales
- Latest buy
- Aug 25, 2017
- Sanofi, 10% owner
Buys and sales on the price
Since 2003By period
Open-market trades| Trades | 3 months | 12 months | Since 2003 |
|---|---|---|---|
| Buys | 0 | 0 | 62 |
| Sales | 14 | 24 | 892 |
| Plan sales | 9 | 18 | 642 |
| Shares bought | 00 | 00 | 8,497,7508.50M |
| Shares sold | 56,48056.5K | 63,44563.4K | 39,632,94639.6M |
| Net shares | −56,480−56.5K | −63,445−63.4K | −31,135,196−31.1M |
| Net value | −$52.9M | −$58.2M | −$12.2B |
Insiders
| Insider | 12 months | Shares held |
|---|---|---|
George Yancopoulos Bd. Co-Chair, President & CSO, Director | — | 1,125,945 as of Jan 5, 2026 |
Leonard S. Schleifer Bd. Co-Chair, President & CEO, Director | — | 687,981 as of Jan 5, 2026 |
Andrew J. Murphy Co-Chief Scientific Officer | −7.6% | 51,193 |
Joseph J. Larosa EVP General Counsel and Secret | −11.3% | 48,128 |
Plew Daniel P. Van EVP & General Mgr, Industrial | — | 35,178 as of Dec 11, 2025 |
Trades
954 trades since 2003| Type | Insider | Role | Shares | Price | Held after | |||
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Sale | Jason PitofskySVP Controller SVP Controller | SVP Controller | 4,062 at $942.19 | $942.19 | $3.83M | −47.4% 4.50K after | 4,499 |
| Nov 3, 2026 | Sale | Huda Y. ZoghbiDirector Director | Director | 7,439 at $970.46 | $970.46 | $7.22M | −81.4% 1.70K after | 1,703 |
| Nov 2, 2026 | Sale | Joseph J. LarosaEVP General Counsel and Secret EVP General Counsel and Secret | EVP General Counsel and Secret | 4,466 at $965.49 | $965.49 | $4.31M | −8.5% 48.1K after | 48,128 |
| Nov 2, 2026 | Sale | George L. SingDirector Director | Director | 21,129 at $964.38 | $964.38 | $20.4M | −43.6% 27.3K after | 27,297 |
| Nov 2, 2026 | Sale | Christine A. PoonDirector Director | Director | 7,830 at $969.09 | $969.09 | $7.59M | −60.0% 5.22K after | 5,219 |
| Oct 30, 2026 | Plan sale | Kathryn GuariniDirector Director | Director | 400 at $900.00 | $900.00 | $360K | −39.9% 603 after | 603 |
| Oct 30, 2026 | Plan sale | Marion McCourtEVP Commercial EVP Commercial | EVP Commercial | 1,132 at $869.43 | $869.43 | $984K | −9.3% 11.1K after | 11,090 |
| Oct 30, 2026 | Plan sale | Michael S. BrownDirector Director | Director | 1,929 at $875.00 | $875.00 | $1.69M | −13.0% 12.9K after | 12,865 |
| Oct 14, 2026 | Plan sale | Andrew J. MurphyCo-Chief Scientific Officer Co-Chief Scientific Officer | Co-Chief Scientific Officer | 4,147 at $772.70 | $772.70 | $3.20M | −7.4% 52.2K after | 52,247 |
| Sep 3, 2026 | Plan sale | Marion McCourtEVP Commercial EVP Commercial | EVP Commercial | 1,131 at $857.39 | $857.39 | $970K | −8.5% 12.2K after | 12,222 |
- Jason Pitofsky$3.83MNov 4, 2026 · Sale4,062 at $942.19SVP Controller−47.4% of holdings, 4.50K after
- Huda Y. Zoghbi$7.22MNov 3, 2026 · Sale7,439 at $970.46Director−81.4% of holdings, 1.70K after
- Joseph J. Larosa$4.31MNov 2, 2026 · Sale4,466 at $965.49EVP General Counsel and Secret−8.5% of holdings, 48.1K after
- George L. Sing$20.4MNov 2, 2026 · Sale21,129 at $964.38Director−43.6% of holdings, 27.3K after
- Christine A. Poon$7.59MNov 2, 2026 · Sale7,830 at $969.09Director−60.0% of holdings, 5.22K after
- Kathryn Guarini$360KOct 30, 2026 · Plan sale400 at $900.00Director−39.9% of holdings, 603 after
- Marion McCourt$984KOct 30, 2026 · Plan sale1,132 at $869.43EVP Commercial−9.3% of holdings, 11.1K after
- Michael S. Brown$1.69MOct 30, 2026 · Plan sale1,929 at $875.00Director−13.0% of holdings, 12.9K after
- Andrew J. Murphy$3.20MOct 14, 2026 · Plan sale4,147 at $772.70Co-Chief Scientific Officer−7.4% of holdings, 52.2K after
- Marion McCourt$970KSep 3, 2026 · Plan sale1,131 at $857.39EVP Commercial−8.5% of holdings, 12.2K after